WO1995023175A1 - Polyester - Google Patents
Polyester Download PDFInfo
- Publication number
- WO1995023175A1 WO1995023175A1 PCT/EP1995/000655 EP9500655W WO9523175A1 WO 1995023175 A1 WO1995023175 A1 WO 1995023175A1 EP 9500655 W EP9500655 W EP 9500655W WO 9523175 A1 WO9523175 A1 WO 9523175A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- product according
- acrylic acid
- substituent
- electrolyte properties
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/68—Polyesters containing atoms other than carbon, hydrogen and oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
- C08G63/60—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from the reaction of a mixture of hydroxy carboxylic acids, polycarboxylic acids and polyhydroxy compounds
Definitions
- the invention relates to new polyesters consisting of a substituent with polyol containing electrolyte properties and polymeric hydroxycarboxylic acid esters, their preparation and their use.
- new branched-chain esters composed of substituents with polyol containing electrolyte properties and poly-milk or copoly-milk glycolic acid residues, their preparation and their use as matrix material for depot forms containing pharmacologically active substances.
- Depot forms can be created in different administered orally, parenterally, ocularly, pulmonally or by sprinkling in wounds.
- depot forms suitable for parenteral application which are also referred to as parenteral retarolu.i ⁇ e ⁇ .
- Parenteral sustained release forms can be formulated as microparticles, implants and fibers.
- Microparticles are of particular interest, since, because of their small dimensions, they can be applied in a suitable medium by means of a syringe over a small diameter injection needle, with comparatively little pain.
- Such formulations are of interest for all pharmacologically active substances when long-lasting, constant systemic or local drug concentrations are desired. They are particularly advantageous for active ingredients which are destroyed or insufficiently absorbed when administered orally and can only be administered parenterally. The latter is the case, for example, with pharmacologically active peptides such as peptide hormones or proteins.
- interleukins interleukins
- interferons IFN
- neurotrophins NT-1 to NT-3
- colony stimulating factors CSF
- epidermal growth factors GEF
- neuronal growth factors prolactin
- prolactin Luteinizing- 5 of the hormone-releasing hormone (LH-RH)
- insulin somatostatin
- glucagon gastrin
- pentagastrin pentagastrin
- urogastron calcitonin
- secretin secretin
- enkephalins endorphins
- angiotensins renin
- bradykinenin tyrocidin
- gramicidins erythropoetin ( EPO)
- .angiopeptin hirudin
- oxytocin vasopressin
- calcitonin gene related peptides CGRP
- BDGF brain derived growth factors
- Biodegradable matrix polymers for drug embedding have already been described in 1973 with US 3,773,919.
- Polymers from hydroxycarboxylic acids, in particular from lactic and / or glycolic acid have been proposed.
- Polymers made from lactic and / or glycolic acid are hydrolyzed in the body to lactic and / or glycolic acid, which are further metabolized to CO2 and water and are therefore particularly suitable for the production of parenteral prolonged-release forms.
- EP 0 058 481 B1 describes the use of a mixture of PLGA which have different molecular weights. This is intended to linearize the release and to adapt the rate of breakdown to the release period.
- the use of polymer mixtures of this type places high demands on the hydrolysis stability of the active ingredient and is not suitable for the production of microparticles.
- EP 0 407 617 describes a biocompatible polyester with increased hydrolysis rate, consisting of saccharides bound to PLA or PLGA.
- the polyesters are proposed as matrix material for depot forms, but a corresponding embodiment is not included.
- Example 26 contains, for example, the in vitro release of washed microparticles containing bromocriptine mesylate produced by spray drying. Despite washing off the active substance adhering to the microparticle surface, 62% of the active substance load was already released after 24 hours.
- the matrix polymers it is often not possible to produce sustained release forms with a sufficiently high active ingredient loading.
- a high active ingredient loading of the slow-release forms is desired, however, since the amount that can be applied in each case is limited by their intramuscular or subcutaneous administration, and the long application intervals sought for slow-release forms can often only be achieved in this way.
- hydrophilic active substances for example those which are present in dissociated form under physiological conditions, cannot therefore be brought into the known, high concentration in the known matrix polymers and show inconsistent active substance release, in particular an increased initial active substance release (burst effect).
- the matrix polymers should enable a high loading of the active ingredient and should release the active ingredient in a sustained manner and release it without fluctuations.
- the speed and total duration of polymer degradation should be adapted to the speed and duration of the active ingredient release, so that after
- a further dose of the depot form can be applied at the release end without the risk of the matrix polymer accumulating in the body.
- the matrix polymers according to the invention can easily be processed into depot shapes.
- known processes such as solvent evaporation or spray drying, they have good particle formation properties and are particularly suitable for the production of microparticles.
- the invention relates to a branched-chain ester of a polyol containing at least one substituent with electrolyte properties with acid residues consisting of polyhydroxycarboxylic acids and having a molecular weight of up to 500,000.
- Substituents with electrolyte properties are understood to be those which are at least partially in dissociated form in the hydrophilic environment.
- the invention also relates to a reaction product of a polyol containing at least one substituent with electrolyte properties and acid residues consisting of polyhydroxycarboxylic acids and having a molecular weight of up to 500,000.
- the substitutes with electrolyte properties contained in the polyesters according to the invention can be formed from a strong or weak acid or a strong or weak base and can also be present in the form of their salts.
- Z- They preferably consist of a strong acid or a weak base and are in the form of their salts.
- the invention therefore also relates to a product in which the substituent having electrolyte properties is formed from a sulfo group, a primary, secondary or tertiary A in or a carboxyl group.
- the polyol containing substituents with electrolyte properties can consist of the same or different alicyclic or aliphatic units which are linked together in a chain and have a linear or cyclic structure.
- Such polyols can be, for example, appropriately substituted poly- or oligomers from carbohydrates, such as inulin, dextrans, xylans, cyclodextrins or from appropriately substituted polymers from the same or different Al-
- ken units such as substituted polyvinyl alcohol or copolymers of substituted or unsubstituted polyvinyl alcohol or partially acetylated polyvinyl alcohol with acrylic acid, ⁇ - or ⁇ -methacrylic acid, acrylamine, ⁇ - or ⁇ -methacrylamine, acrylonitrile or - or ⁇ -methacrylonitrile.
- Sulphated polyvinyl alcohol or its copolymers can be prepared by mixing the corresponding polyvinyl acetate or its copolymers into a suitable alcohol containing H2SO4 / SO3, such as ethanol, with “1” sulfated and then neutralized. If the reaction is carried out, for example, in ethanol containing 5% H2SO4 / SO3 and neutralized, about 20% of the hydroxyl groups are sulfated.
- Copolymers containing polyvinyl alcohol or partially acetylated polyvinyl alcohol can be prepared by acidic or alkaline hydrolysis of the corresponding copolymer containing polyvinyl acetate.
- the polymeric hydroxycarboxylic acid residues can be composed of one, two, three or more specific hydroxycarboxylic acids.
- hydroxycarboxylic acids which can be used according to the invention are lactic acid, glycolic acid, ⁇ -hydroxypropionic acid, ⁇ -hydroxybutyric acid, ⁇ -hydroxyvaleric acid or € -hydroxycaproic acid.
- Polyhydroxycarboxylic acids from lactic and / or glycolic acid are preferred.
- Copolymers of lactic and glycolic acid, the acid residues of which consist of 25 to 50 mol% of glycolic acid units, are particularly preferred.
- the lactic acid units can be present in optically pure form (D- or L-lactic acid) or as a mixture thereof.
- the substituted polyol esters according to the invention can be prepared by a correspondingly substituted polyol with one or more hydroxycarboxylic acid / s in dimeric or lactone form in the presence of a catalyst suitable for ring-opening polymerization, e.g. Tin, zinc, tin chloride, zinc chloride, titanium tetrachloride, aluminum chloride, tin octoate, or aluminum triisopropyl oxide is reacted. Tin octoate and aluminum triisopropyl oxide are preferably used.
- reaction components are mixed with one another and with the catalyst and reacted at elevated temperature.
- the resulting compounds according to the invention can be isolated and purified in a manner known per se. They are particularly suitable as a depot matrix material for medicinal products.
- Example 1 28 g of D, L-lactide (LA), 22 g of glycolide (GA) and 0.5 g of DSS (Sigma, Mw 500,000) with 1-2 SO 3 groups per monomer were placed in a 100 ml nitrogen flask with Flushed with nitrogen and heated in an oil bath in an oil bath heated to 170 ° C. under a nitrogen atmosphere until the monomers have melted. Subsequently, 200 mg of tin octoate were injected into the melt with constant stirring and the reaction temperature was lowered to 150 ° C. after half an hour, where the reaction was continued for a further 3.5 hours.
- LA D, L-lactide
- GA glycolide
- DSS Sigma, Mw 500,000
- the product was dissolved in 100 ml of methylene chloride and washed 3 times with distilled water in order to remove DSS residues.
- the polymer solution was then filtered through a glass suction filter (# 3), the product was precipitated in ethanol and dried to constant weight in vacuo for a few days.
- Example 2 28 g D, L-lactide (LA), 22 g glycolide (GA) and 0.5 g DEAED
- esters prepared were dissolved in CDCI3 and characterized at 25 ° C. and with the addition of tetramethylsilane (TMS) as a reference by NMR spectroscopy.
- TMS tetramethylsilane
- the molecular weights of the esters produced were determined by gel permeation chromatography in methylene chloride. The determination was made using a temperature-controlled column combination
- Lichrogel PS mix and Lichrogel PS 40, 10 ⁇ m, Merck performed at 25 ° C using a differential refractometer (Merck-Hitachi RI-71). Polystyrene standards were used for the calibration (Merck, Mw 3,250; 5,100; 19,600; 34,500 and 87,000).
- 10% (w / v) polymer solutions were prepared in methylene chloride. These were poured onto Teflon-coated plates and the solvent was first removed at RT for 48 h, then in a vacuum at room temperature. After drying to constant weight, 100-200 ⁇ m thick films were obtained, which were cut into 20 mm ⁇ 10 mm parts.
- Figure 1 contains a representation of the molecular weight reduction of polymer films produced from polymers 2 and 3.
- Weight loss was determined gravimetrically. For this purpose, a polymer film part was placed in a nylon mesh, sealed by heating and transferred to a shaking bath filled with distilled water and heated to 37 ° C. After defined time intervals, the network was removed in a vacuum RT dried to constant weight and the remaining mass determined.
- Figure 2 contains a graphic representation of the polymer mass remaining after the respective time intervals of the polymer films produced from the polymers 5 and 13 (Table 1).
- the polymers according to the invention Compared to conventional linear polylactide coglycolides, the polymers according to the invention have a significantly increased molecular mass reduction which is accompanied by a likewise significantly increased mass loss of the polymer.
- microparticles were produced by means of solvent evaporation.
- an RSA solution 25%) was added to a 20% polymer solution (methylene chloride), with intensive homogenization with a gear rim dispersing rod, so that RSA and ol ' ⁇ r were present in a weight ratio of 10%.
- This emulsion was injected with stirring into a 0.5% PVA solution, from which the microparticles formed after 3 hours of stirring were filtered off. After drying (in a vacuum at RT), the microparticles were stored at 5 ° C.
- the degree of RSA loading of the microparticles was determined photometrically at 278 nm after dissolution in acetonitrile and extraction with water.
- the particle size was determined by means of laser light scattering. The results obtained are summarized in Table 2.
- microparticles About 100 mg of microparticles (exactly weighed) were transferred to closable test tubes (20 ml) and 5 ml of phosphate buffer solution (pH 7.2) were added. The sealed jars were moved at 37 ° C in a rotating metal block thermostat (Rotatherm) at 15 rpm. After predetermined time intervals, the microparticles were centrifuged at 4000 rpm for 30 min, 3 ml of sample solution were taken in each case, replaced by fresh phosphate buffer solution (pH 7.2) and the release was continued. The RSA concentration in the sample solution was determined photometrically at 278 nm.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Polyesters Or Polycarbonates (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP95911254A EP0797609B1 (de) | 1994-02-25 | 1995-02-23 | Polyester |
US08/817,860 US5929196A (en) | 1994-02-25 | 1995-02-23 | Polyesters of a polyhydroxycarboxylic acid and a polyol having a substituent with electrolyte properties |
AT95911254T ATE192765T1 (de) | 1994-02-25 | 1995-02-23 | Polyester |
DE59508331T DE59508331D1 (en) | 1994-02-25 | 1995-02-23 | Polyester |
DK95911254T DK0797609T3 (da) | 1994-02-25 | 1995-02-23 | Polyestere |
CA002196698A CA2196698C (en) | 1994-02-25 | 1995-02-23 | Polyesters |
GR20000401812T GR3034115T3 (en) | 1994-02-25 | 2000-08-02 | Polyesters |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DEP4406172.2 | 1994-02-25 | ||
DE4406172A DE4406172C2 (de) | 1994-02-25 | 1994-02-25 | Polyester |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995023175A1 true WO1995023175A1 (de) | 1995-08-31 |
Family
ID=6511221
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1995/000655 WO1995023175A1 (de) | 1994-02-25 | 1995-02-23 | Polyester |
Country Status (10)
Country | Link |
---|---|
US (1) | US5929196A (de) |
EP (1) | EP0797609B1 (de) |
AT (1) | ATE192765T1 (de) |
CA (1) | CA2196698C (de) |
DE (2) | DE4406172C2 (de) |
DK (1) | DK0797609T3 (de) |
ES (1) | ES2146751T3 (de) |
GR (1) | GR3034115T3 (de) |
PT (1) | PT797609E (de) |
WO (1) | WO1995023175A1 (de) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5929196A (en) * | 1994-02-25 | 1999-07-27 | Schwarz Pharma Ag | Polyesters of a polyhydroxycarboxylic acid and a polyol having a substituent with electrolyte properties |
US5942253A (en) * | 1995-10-12 | 1999-08-24 | Immunex Corporation | Prolonged release of GM-CSF |
DE19839515A1 (de) * | 1998-08-29 | 2000-03-09 | Thomas Kissel | Neue pharmazeutische Zubereitung, enthaltend kolloidale Polymer-Wirkstoff-Assoziate, insbesondere auch für mucosale Wirkstoffverabreichung |
WO2002038129A2 (en) * | 2000-11-08 | 2002-05-16 | Creative Peptides Sweden Ab | Delayed-release pharmaceutical formulations containing proinsulin c-peptide |
KR100356737B1 (ko) * | 1997-01-24 | 2003-02-05 | 슈바르츠 파르마 악티엔게젤샤프트 | 폴리에스테르의제조방법 |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19545257A1 (de) | 1995-11-24 | 1997-06-19 | Schering Ag | Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln |
US6451346B1 (en) * | 1998-12-23 | 2002-09-17 | Amgen Inc | Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents |
DE60003803T2 (de) | 1999-04-16 | 2004-06-03 | Novo Nordisk A/S | Trockene formbare arzneistoffformulierung |
US6616944B2 (en) * | 2000-03-08 | 2003-09-09 | Medinnova Gesellschaft Fur Medizinsche Innovationen Aus Adkademischer Forschung Mbh | Self-assembling colloidal carriers for protein delivery |
ES2345182T3 (es) * | 2000-03-08 | 2010-09-17 | Nanohale Gmbh | Vehiculos nanoparticulados coloidales que contienen polimeros en peine solubles en agua cargados o sin cargar y su uso para administracion mucosa. |
WO2002005744A1 (en) * | 2000-07-14 | 2002-01-24 | Novo Nordisk A/S | Method of moulding a pharmaceutical composition in a packaging material |
US6562603B2 (en) * | 2000-08-04 | 2003-05-13 | E. I. Du Pont De Nemours And Company | 3-hydroxycarboxylic acid production and use in branched polymers |
US6911204B2 (en) | 2000-08-11 | 2005-06-28 | Favrille, Inc. | Method and composition for altering a B cell mediated pathology |
KR20030064377A (ko) * | 2000-08-11 | 2003-07-31 | 파브릴, 인크. | T 세포 매개 병증을 개선시키기 위한 방법 및 조성물 |
DE10055742B4 (de) * | 2000-11-10 | 2006-05-11 | Schwarz Pharma Ag | Neue Polyester, Verfahren zu ihrer Herstellung und aus den Polyestern hergestellte Depot-Arzneiformen |
JP2004516263A (ja) | 2000-12-21 | 2004-06-03 | ネクター セラピューティクス | 疎水性活性剤を含有するマイクロ粒子の製造のための誘発相転移法 |
DE10111767B4 (de) * | 2001-03-12 | 2005-03-24 | Schwarz Pharma Ag | Verfahren zur Herstellung von Polyestern aus Hydroxycarbonsäuren und Polyolen durch Polykondensation |
US20040185101A1 (en) * | 2001-03-27 | 2004-09-23 | Macromed, Incorporated. | Biodegradable triblock copolymers as solubilizing agents for drugs and method of use thereof |
US8454997B2 (en) | 2001-12-18 | 2013-06-04 | Novo Nordisk A/S | Solid dose micro implant |
US7649023B2 (en) * | 2002-06-11 | 2010-01-19 | Novartis Ag | Biodegradable block copolymeric compositions for drug delivery |
US7037983B2 (en) | 2002-06-14 | 2006-05-02 | Kimberly-Clark Worldwide, Inc. | Methods of making functional biodegradable polymers |
US20030232088A1 (en) * | 2002-06-14 | 2003-12-18 | Kimberly-Clark Worldwide, Inc. | Materials with both bioadhesive and biodegradable components |
US6992543B2 (en) * | 2002-11-22 | 2006-01-31 | Raytheon Company | Mems-tuned high power, high efficiency, wide bandwidth power amplifier |
US7888445B2 (en) | 2005-07-26 | 2011-02-15 | Knauf Insulation Gmbh | Fibrous products and methods for producing the same |
EP2108006B8 (de) | 2007-01-25 | 2020-11-11 | Knauf Insulation GmbH | Bindemittel und damit hergestellte materialien |
WO2008089850A1 (en) | 2007-01-25 | 2008-07-31 | Knauf Insulation Limited | Mineral fibre board |
WO2008089847A1 (en) | 2007-01-25 | 2008-07-31 | Knauf Insulation Limited | Composite wood board |
CA2683706A1 (en) | 2007-04-13 | 2008-10-23 | Knauf Insulation Gmbh | Composite maillard-resole binders |
GB0715100D0 (en) | 2007-08-03 | 2007-09-12 | Knauf Insulation Ltd | Binders |
US20090186177A1 (en) * | 2008-01-22 | 2009-07-23 | Eastman Chemical Company | Polyester melt phase products and process for making the same |
WO2011015946A2 (en) | 2009-08-07 | 2011-02-10 | Knauf Insulation | Molasses binder |
JP5992903B2 (ja) | 2010-05-07 | 2016-09-14 | ナフ インサレーション エセペーアールエル | 炭水化物結合剤およびそれを用いて作製される材料 |
KR101837215B1 (ko) | 2010-05-07 | 2018-03-09 | 크나우프 인설레이션, 인크. | 탄수화물 폴리아민 결합제 및 이를 이용하여 제조된 물질 |
CA2801546C (en) | 2010-06-07 | 2018-07-10 | Knauf Insulation | Fiber products having temperature control additives |
CA2834816C (en) | 2011-05-07 | 2020-05-12 | Knauf Insulation | Liquid high solids binder composition |
GB201206193D0 (en) | 2012-04-05 | 2012-05-23 | Knauf Insulation Ltd | Binders and associated products |
GB201214734D0 (en) | 2012-08-17 | 2012-10-03 | Knauf Insulation Ltd | Wood board and process for its production |
EP2928936B1 (de) | 2012-12-05 | 2022-04-13 | Knauf Insulation SPRL | Bindemittel |
PL3102587T3 (pl) | 2014-02-07 | 2019-01-31 | Knauf Insulation, Inc. | Nieutwardzone wyroby o ulepszonym okresie trwałości |
GB201408909D0 (en) | 2014-05-20 | 2014-07-02 | Knauf Insulation Ltd | Binders |
GB201517867D0 (en) | 2015-10-09 | 2015-11-25 | Knauf Insulation Ltd | Wood particle boards |
GB201610063D0 (en) | 2016-06-09 | 2016-07-27 | Knauf Insulation Ltd | Binders |
GB201701569D0 (en) | 2017-01-31 | 2017-03-15 | Knauf Insulation Ltd | Improved binder compositions and uses thereof |
GB201804908D0 (en) | 2018-03-27 | 2018-05-09 | Knauf Insulation Ltd | Binder compositions and uses thereof |
GB201804907D0 (en) | 2018-03-27 | 2018-05-09 | Knauf Insulation Ltd | Composite products |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3430852A1 (de) * | 1983-08-26 | 1985-03-14 | Sandoz-Patent-GmbH, 7850 Lörrach | Neue ester, deren herstellung und verwendung |
WO1993022362A1 (de) * | 1992-04-23 | 1993-11-11 | Basf Aktiengesellschaft | Verfahren zur herstellung von polyestern aus citronensäure und polyhydroxyverbindungen und ihre verwendung |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
IE52535B1 (en) * | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
IN166447B (de) * | 1985-11-27 | 1990-05-12 | Ethicon Inc | |
WO1990008793A1 (fr) * | 1989-01-27 | 1990-08-09 | Mitsui Toatsu Chemicals, Inc. | Polyester biocompatible et production de ce compose |
DE4406172C2 (de) * | 1994-02-25 | 2003-10-02 | Sanol Arznei Schwarz Gmbh | Polyester |
-
1994
- 1994-02-25 DE DE4406172A patent/DE4406172C2/de not_active Expired - Fee Related
-
1995
- 1995-02-23 DK DK95911254T patent/DK0797609T3/da active
- 1995-02-23 US US08/817,860 patent/US5929196A/en not_active Expired - Fee Related
- 1995-02-23 PT PT95911254T patent/PT797609E/pt unknown
- 1995-02-23 ES ES95911254T patent/ES2146751T3/es not_active Expired - Lifetime
- 1995-02-23 AT AT95911254T patent/ATE192765T1/de not_active IP Right Cessation
- 1995-02-23 WO PCT/EP1995/000655 patent/WO1995023175A1/de active IP Right Grant
- 1995-02-23 DE DE59508331T patent/DE59508331D1/de not_active Expired - Fee Related
- 1995-02-23 CA CA002196698A patent/CA2196698C/en not_active Expired - Fee Related
- 1995-02-23 EP EP95911254A patent/EP0797609B1/de not_active Expired - Lifetime
-
2000
- 2000-08-02 GR GR20000401812T patent/GR3034115T3/el not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3430852A1 (de) * | 1983-08-26 | 1985-03-14 | Sandoz-Patent-GmbH, 7850 Lörrach | Neue ester, deren herstellung und verwendung |
WO1993022362A1 (de) * | 1992-04-23 | 1993-11-11 | Basf Aktiengesellschaft | Verfahren zur herstellung von polyestern aus citronensäure und polyhydroxyverbindungen und ihre verwendung |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5929196A (en) * | 1994-02-25 | 1999-07-27 | Schwarz Pharma Ag | Polyesters of a polyhydroxycarboxylic acid and a polyol having a substituent with electrolyte properties |
US5942253A (en) * | 1995-10-12 | 1999-08-24 | Immunex Corporation | Prolonged release of GM-CSF |
US6274175B1 (en) | 1995-10-12 | 2001-08-14 | Immunex Corporation | Prolonged release of GM-CSF |
KR100356737B1 (ko) * | 1997-01-24 | 2003-02-05 | 슈바르츠 파르마 악티엔게젤샤프트 | 폴리에스테르의제조방법 |
DE19839515A1 (de) * | 1998-08-29 | 2000-03-09 | Thomas Kissel | Neue pharmazeutische Zubereitung, enthaltend kolloidale Polymer-Wirkstoff-Assoziate, insbesondere auch für mucosale Wirkstoffverabreichung |
DE19839515B4 (de) * | 1998-08-29 | 2012-02-02 | Nanohale Gmbh | Neue pharmazeutische Zubereitung, enthaltend kolloidale Polymer-Wirkstoff-Assoziate, insbesondere auch für mucosale Wirkstoffverabreichung |
WO2002038129A2 (en) * | 2000-11-08 | 2002-05-16 | Creative Peptides Sweden Ab | Delayed-release pharmaceutical formulations containing proinsulin c-peptide |
WO2002038129A3 (en) * | 2000-11-10 | 2003-02-13 | Creative Peptides Sweden Ab | Delayed-release pharmaceutical formulations containing proinsulin c-peptide |
Also Published As
Publication number | Publication date |
---|---|
EP0797609B1 (de) | 2000-05-10 |
DK0797609T3 (da) | 2000-08-07 |
DE4406172A1 (de) | 1995-08-31 |
ES2146751T3 (es) | 2000-08-16 |
CA2196698A1 (en) | 1995-08-31 |
ATE192765T1 (de) | 2000-05-15 |
DE4406172C2 (de) | 2003-10-02 |
CA2196698C (en) | 2000-01-11 |
DE59508331D1 (en) | 2000-06-15 |
US5929196A (en) | 1999-07-27 |
PT797609E (pt) | 2000-10-31 |
GR3034115T3 (en) | 2000-11-30 |
EP0797609A1 (de) | 1997-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE4406172C2 (de) | Polyester | |
DE4021517B4 (de) | Formulierungen mit verlangsamter Freisetzung wasserlöslicher Peptide | |
DE69633399T2 (de) | Verlängerte freisetzung von gm-csf | |
DE3430852C2 (de) | Neue Ester, deren Herstellung und Verwendung | |
US4130639A (en) | Absorbable pharmaceutical compositions based on isomorphic copolyoxalates | |
EP1345979B1 (de) | Neue polyester, verfahren zu ihrer herstellung und aus den polyestern hergestellte depot-arzneiformen | |
AT408609B (de) | Zubereitung zur stetigen und kontrollierten abgabe von medikamentösen substanzen und verfahren zu deren herstellung | |
EP0454044B1 (de) | Pharmakologische Zubereitung, enthaltend Polyelektrolytkomplexe in mikropartikulärer Form und mindestens einen Wirkstoff | |
DE4224401A1 (de) | Neue biologisch abbaubare Polymere für die Arzneistoffgalenik | |
JP3834331B2 (ja) | 表面活性剤を含有しない生体再吸収性重合体微小球、その製造及び薬剤としてその応用 | |
DE2051580A1 (de) | Polylactid Arzneimittel Mischungen | |
WO1996028143A1 (de) | Polypeptid-enthaltende pharmazeutische darreichungsformen in form von mikropartikeln und verfahren zu deren herstellung | |
DE2723911A1 (de) | Unter normalbedingungen festes bioresorbierbares hydrolysierbares polymeres reaktionsprodukt | |
DE2842089A1 (de) | Arzneimittel mit verzoegerter wirkstoffabgabe | |
EP0245840B1 (de) | Biologisch abbaubare Polymere für Depotzubereitungen mit kontrollierter Wirkstoffabgabe | |
EP0778304B1 (de) | Hydrophobe resorbierbare Polyester und deren Verwendung | |
EP0439846B1 (de) | Biologisch abbaubare Polymere, Verfahren zu ihrer Herstellung und Verwendung derselben für Depotzubereitungen mit kontrollierter Wirkstoffabgabe | |
DE2821949A1 (de) | Arzneimittel mit depotwirkung | |
DE3835099A1 (de) | Pharmazeutische zusammensetzung | |
DE10111767B4 (de) | Verfahren zur Herstellung von Polyestern aus Hydroxycarbonsäuren und Polyolen durch Polykondensation | |
DE19542837A1 (de) | Polypeptid-enthaltende pharmazeutische Darreichungsformen in Form von Mikropartikeln und Verfahren zu deren Herstellung | |
AT397804B (de) | Biologisch abbaubare polymere für depotzubereitungen mit kontrollierter wirkstoffabgabe, verfahren zu ihrer herstellung und ihre verwendung | |
CH672133A5 (en) | New poly-ol ester] deriv. contg. poly- or co:poly-lactic acid residues - useful as degradable matrix for slow release drug formulations | |
DD301542A7 (de) | Verfahren zur herstellung monomerfreier, aliphatischer, biologisch abbaubarer homo- und copolyester | |
KR19980066442A (ko) | 폴리에스테르 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA CN JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1995911254 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2196698 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08817860 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1995911254 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995911254 Country of ref document: EP |